Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: Focus on ciprofloxacin

International Journal of Antimicrobial Agents

Volumn 10, Issue 4, 1998, Pages 297-302

  Blondeau, J M ^a   Suter, M E ^a   Borsos, S ^a   Misfeldt, C ^a  

^a Saskatoon Dist Hlth St Paul's H ^*  (Canada)

Author keywords

Pseudomonas aeruginosa; Resistance; Susceptibility

Indexed keywords

ANTIINFECTIVE AGENT; AZLOCILLIN; AZTREONAM; CARBENICILLIN; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; IMIPENEM; MEZLOCILLIN; NETILMICIN; TICARCILLIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CANADA; CYSTIC FIBROSIS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SOFT TISSUE INFECTION;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CANADA; CARBENICILLIN; CEFTAZIDIME; CEPHALOSPORINS; CIPROFLOXACIN; DRUG RESISTANCE, MICROBIAL; GEOGRAPHY; HOSPITALS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TICARCILLIN; URINARY TRACT INFECTIONS;

EID: 0032434678     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(98)00049-1     Document Type: Article

References (17)

1. Pollack M Pseudomomas aeruginosa. Mandell GL, Douglas RG, Bennett JE Principles and Practices of Infectious Diseases, Third Edition. 1990;1673-1691 Churchill Livingstone, New York.
2. Committee on Antimicrobial Agents, Canadian Infectious Diseases Society, Louie TJ. Ciprofloxacin: an oral quinolone for the treatment of infections with Gram-negative pathogens. Can Med Assoc J 1994;150:669-676.
3. Walker RC, Wright AJ The fluoroquinolones. Mayo Clin Proc. 66:1991;1249-1259.
4. Wiedeman B, Zuhlsdorf MT Brief report: resistance development to fluoroquinolones in Europe. Am J Med. 87(supp.5A):1989;9s-11.
5. Felmingham D, O'Hare MD, Robbins MJ et al. Comparative in vitro studies with 4-quinolone antimicrobials. Drugs Expt Clin Res. XI:1985;317-329.
6. Parry MF, Panzer KB, Yukna ME. Quinolone resistance: susceptibility data from a 300-bed community hospital. Am J Med 1989;87 Suppl 5:12-16.
7. Sanders CC Ciprofloxacin: in vitro activity mechanisms of action and resistance. Rev Infect Dis. 10:1988;516-527.
8. Blondeau JM, Yaschuk Y, the Canadian Ciprofloxacin Study Group. Canadian ciprofloxacin susceptibility study: a comparative study from 15 medical centers. Antimicrob Agents Chemother 1996;40:1729-1732.
9. National Committee for Clinical Laboratory Standards. Approved Standard M7-A3: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, National Committee for Clinical Laboratory Standards, Villanova, PA, 1994.
10. Chamberland S, L'Ecuyer J, Lessard C et al. Antibiotic susceptibility profiles of 941 Gram-negative bacterial isolates from septicemic patients throughout Canada. Clin Infect Dis. 15:1992;615-628.
11. Pieroni P, Goodfellow J, Reesor L, Louie M, Simor AE. Antimicrobial susceptibilities of blood culture isolates from a Canadian tertiary care hospital before and after introduction of ciprofloxacin. Thirty-fifth meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California September 1995;17-20, Abstract E129.
12. Hoban DJ, Jones RN, The Canadian Ofloxacin Study Group. Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Chemother 1995;41:34-38.
13. Coronado VG, Edwards JR, Culver DH, Gaynes RP, the National Nosocomial Infections Surveillance (NNIS) System. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Cont Hosp Epidemiol 1995;16:71-75.
14. Tillotson G, Culshaw K, O'Keeffe B. Gram-negative bacterial susceptibility to ciprofloxacin-a six year UK perspective. Sixth International Congress of Infectious Disease, Prague, Czech Republic 1994, Abstract 136.
15. Forward KR, Franks P, Low DE. A cross Canada surevey of resistance to piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 1996;15-18, Abstract E14.
16. Forward KR, Low DE, Laverdiere M Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates. Can J Infect Dis. 8:1997;147-153.
17. Hoban DJ, Jones RN. The North American component (USA Canada) of an international comparative MIC trial monitoring ofloxacin resistance. Drugs 1993;45 Suppl 3:167-169.